Medexus Pharmaceuticals (MDP) AGM 2024 summary

Opening remarks and agenda

• Meeting opened with a welcome from the Chair and a reminder of recording and privacy protocols.

• CEO provided an update on the Treosulfan FDA review and its significance.

• Agenda included presentation of financial statements, election of directors, and reappointment of auditors.

Strategic initiatives and plans

• FDA review of Treosulfan NDA extended to January 30, 2025, with no new clinical data required.

• Preparations underway for potential US commercial launch of Treosulfan in the first half of 2025.

• Treosulfan approval expected to significantly grow revenues in coming years.

Financial performance review

• Consolidated financial statements for years ended March 31, 2024 and 2023 presented to shareholders.

• Auditor's report distributed to requesting shareholders and available online.